CS Paper Radar

A curated multi-endpoint drug-protein bioactivity dataset with construct-aware protein targets

Lina Abou-Abbas, Nour Mhanna, Hasan Bazzi, Sleiman El Hajj, Abdulkader Helwan, Rabah Omrani, Khadidja Henni

cs.LG ·submitted 2026-10-23 11:07 UTC · v1
dataset

Abstract

Public drug-protein bioactivity resources commonly identify targets by UniProt accession, although one accession may represent distinct experimental sequences. We present Curate-DTI, a construct-aware dataset derived from the 1 July 2026 BindingDB export, with IC50, Ki, Kd and EC50 processed independently. The release contains 2,919,717 measurements, 1,291,872 standardized ligands, 9,668 sequence-defined protein entities and 2,275,683 endpoint-specific interactions spanning 8,336 reviewed UniProt accessions. Protein entities combine the accession with the reported experimental sequence, preserving constructs that accession-only processing would merge. Across the four endpoints, 4,204 endpoint-specific ligand-accession groups showed different classification labels across sequence-defined protein entities. Exact and inequality-qualified observations provide relation-aware classification evidence, whereas regression targets use exact values only. Connected Parquet tables preserve individual measurements, standardized structures, protein sequences, aggregated interactions and available assay and source provenance. The resource supports endpoint-specific classification and regression while allowing users to select molecular representations, protein representations and evaluation splits. Preprocessing code, a column dictionary, exclusion reports and validation summaries accompany the release.

Closest papers

Nearest neighbours by meaning across the whole index.

ProbeMatchDTI: Probe-Driven Multi-Scale Biochemical Pattern Matching for Drug-Target Interaction Prediction

cs.LG cs.AI ·2026-09-02 ·Quan Hao, Mengyue Fan, Zifan Dong, Youru Li, Jianduo Zhao +6 more
code/data similarity 0.67
Abstract

Drug-target interaction (DTI) prediction is an important task in AI-driven drug discovery. Although recent biochemical representation learning methods have improved DTI prediction, their passive feature aggregation tends to favor dominant molecular patterns while suppressing weak yet binding-relevant signals, such as functional groups and residue-context patterns, limiting the modeling of multi-scale biochemical correspondences. To address this issue, we propose ProbeMatchDTI, a pattern-probe-driven framework comprising IterProbe and BindingProbe. IterProbe explicitly retains contextual states across refinement depths and uses learnable probes to select them at each position before cross-entity matching, thereby preserving weak biochemical patterns and strengthening associations among functional groups, local motifs, and molecular scaffolds. BindingProbe then characterizes cross-entity drug-protein complementarity at local biochemical-unit and whole-pair levels, jointly modeling fine-grained interactions and multi-scale correspondences while preserving weaker binding-relevant associations. Extensive experiments demonstrate the superiority of ProbeMatchDTI, achieving 2.0% and 0.5% higher AUC-ROC on BindingDB and DrugBank, respectively. Feature-level pattern analyses further characterize its probe-driven behavior in cross-scale biochemical pattern matching. We further connect ProbeMatchDTI predictions with an evidence-guided downstream drug-discovery workflow, demonstrating their utility for candidate refinement and validation planning. Our code is available at https://github.com/developer-hq/ProbeMatchDTI

0.28

Feature Selection for Tabular Foundation Models: Exploring Feature Utility in Low-Data Molecular Prediction

cs.LG ·2026-09-25 ·Yiqi Yao, Miquel Duran-Frigola
code/data similarity 0.65
Abstract · 34 pages, 13 figures, 21 tables, 11 appendices. v3: revised and expanded with held-out FS-Mol test evaluations. Code: https://github.com/ers…

Choosing features is difficult with few labeled molecules, even for a tabular foundation model that learns in context. We study this problem with TabPFN for low-data molecular property prediction, separating input width, feature meaning, and predictive usefulness while keeping contexts, query molecules, and predictor settings matched. On ADME/Tox assays from Therapeutics Data Commons, endpoint-matched assay predictions improve a compact RDKit descriptor baseline, and a provenance audit shows that most audited query molecules already occur in the predictors' training sources. Across 77 FS-Mol development tasks and 157 held-out test assays drawn from ChEMBL, broad RDKit descriptor and fingerprint families provide a strong default, rank-averaging TabPFN with support-fitted fingerprint forests improves upon both models, and learned weighting of family predictions adds further gains at a larger prediction budget. A utility-trained selector builds a traceable 16-column input from 238 sourceassay predictors, improving upon the baseline while trailing wider representations and equalwidth structural SVD coordinates. Named outputs identify what each feature predicts and where it comes from. Their usefulness for a new assay is assessed alongside the other input features, and paired removal and replacement tests measure what each selected output contributes. Together, these studies offer a protocol for evaluating feature selection, representation choice, and data provenance with a fixed tabular foundation model for few-shot molecular property prediction.

0.36

On the Selectivity of Generative Models in Structure-Based Drug Design

cs.LG cs.AI ·2026-10-16 ·Ella Miray Rajaonson, Jungyoon Lee, William Chau, Alan Aspuru-Guzik, Benjamin Sanchez-Lengeling +3 more
top venuebenchmarkcode/data similarity 0.65
Abstract · Accepted as a Presentation at the Neural Information Processing Systems 2026

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.

0.44

Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

cs.LG q-bio.QM ·2026-08-11 ·Vincent Lavelle, Yitan Zhu, Kaitlyn Marlor, Thomas Brettin, Rick Stevens
benchmarkdataset similarity 0.64
Abstract

Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.

0.04

ColdDDI: Evaluating Knowledge Utilization in Cold-Start Drug-Drug Interaction Prediction

cs.LG cs.CL ·2026-10-04 ·Jiheng Liang, Chen Zhao, Di Wu, Chenyang Bu, Yunpeng Hong +2 more
publishedbenchmarkcode/data similarity 0.64
Abstract · Accepted at NeurIPS 2026 (poster). Code: https://github.com/0217ljh/ColdDDI-NeurIPS2026

Cold-start drug-drug interaction (DDI) prediction tests whether models can identify clinically significant interactions for drugs without training-time interaction history. Existing benchmarks mostly report aggregate edge-prediction scores, leaving a key evaluation question unanswered: when models receive molecular, textual, or knowledge-graph (KG) evidence, do they actually use the evidence that pharmacologically supports the interaction? We introduce ColdDDI, a reconstructible diagnostic benchmark built from DrugBank 5.1.13, with 1,900 approved small-molecule drugs and 565,731 positive DDI pairs. ColdDDI evaluates pairs with zero, one, or two unseen drugs. It also annotates each interaction by whether it changes drug exposure or drug effect, and by whether the biomedical knowledge graph contains shared enzymes, transporters, or targets that can plausibly mediate the interaction. These annotations separate evidence availability from predictive dependence. We evaluate eight conventional DDI methods and 13 LLMs; for open-weight LLMs, we test five prompt patterns and use masking, drug replacement, and channel-sensitivity metrics to probe knowledge utilization. ColdDDI exposes that, in the hardest split where both drugs are unseen, the main performance divide is mediator availability. A fine-tuned 1B LLM recovers 89-93% of interactions with a shared enzyme, transporter, or target, but only 40-62% without such a mediator. More importantly, KG-provided evidence is not always used; several KG-augmented baselines change little when the shared mediator is masked or disrupted, whereas fine-tuned LLMs respond strongly to this intervention. Thus, ColdDDI evaluates knowledge utilization rather than knowledge access alone, showing where cold-start DDI models rely on mechanistic evidence and where they fail despite receiving it. Code is available at https://github.com/0217ljh/ColdDDI-NeurIPS2026.

0.39

Generative Retrieval for Reverse Target Fishing with a Proteome-Scale Benchmark

cs.LG ·2026-10-17 ·Zhichao Deng, Haichuan Tan, Xin Hong, Huaizhi Wang, Tao Huang +2 more
benchmark similarity 0.64
Abstract · 27 pages, 6 figures, 4 tables

Reverse target fishing identifies protein targets for a query molecule and is central to drug discovery and repurposing. Discriminative approaches adapted from virtual screening face sparse, long-tailed associations and missing-not-at-random measurements: treating unrecorded pairs as negatives can suppress genuine targets. We reformulate the task as generative retrieval and introduce GenFish. Residual vector quantization converts frozen protein language model features into shared semantic identifiers. Given a molecular fingerprint, GenFish autoregressively models codes conditioned on the query and preceding code, ranking proteins by identifier likelihood without explicitly labeling unrecorded pairs as negatives. We introduce ProTargetBench, the first proteome-scale benchmark for reverse target fishing to jointly support measured-panel discrimination and full-catalogue recovery of experimentally recorded positives. Covering 20,431 UniProt-reviewed human proteins, it integrates curated bioactivity evidence and distinguishes experimental inactivity from unmeasured associations. On 198 held-out molecules, GenFish achieves higher mean performance across all three full-catalogue retrieval metrics than four discriminative neural baselines and three non-neural baselines, including ligand-based methods. A controlled positive-hiding experiment shows that targeted removal of false-negative competition improves contrastive retrieval beyond matched random masking; GenFish remains stronger under the same incomplete supervision. Pfam alignment indicates that the semantic identifiers capture biologically meaningful relationships among proteins. These results establish generative retrieval as a principled paradigm for reverse target fishing under incomplete bioactivity records.

0.30

SpecOpt: Contact-Diff Reasoning for Agentic Molecule Optimization Toward Binding Specificity

cs.AI ·2026-09-18 ·Thao Nguyen, Heng Ji
benchmark similarity 0.63
Abstract

Off-target protein binding is a major source of adverse effects for small-molecule drugs, yet most structure-based molecular design methods focus on generating selective compounds de novo rather than improving the selectivity of existing, well- characterized drugs. We introduce specificity optimization (SpecOpt), a molecular design task that seeks constrained structural modifications to an existing compound that increase its binding preference for an intended target over known off-targets while preserving its structural identity and drug-like properties. To enable systematic evaluation, we construct a ChEMBL-derived benchmark from compound-target interaction data, identifying intended targets through curated drug-mechanism annotations and off- targets through measured activities. We then develop an agentic framework that docks each compound against its intended target and off-targets, compares the resulting poses through residue-aware atom-protein contacts, and provides these differential interactions to a large language model to propose targeted structural modifications. Candidates are retained only if they satisfy molecular similarity, ADMET, and target-off-target docking selectivity criteria. On 915 compounds, the agent improves the target- off-target binding gap for 84.8% of compounds, shifting the mean gap from -0.72 to +0.47 kcal/mol while maintaining a mean Tanimoto similarity of 0.72 to the starting compounds. Ablation studies identify residue-specific contact information as the critical optimization signal: replacing residue identities with binary contact indicators eliminates improvement on all 29 ablation compounds. These results establish SpecOpt as a distinct molecular design problem and demonstrate residue-aware differential interactions as an effective signal for improving the specificity of existing compounds.

0.08

HierDTA: Hierarchical Structure-Aware Representation Learning for Drug--Target Affinity Prediction

cs.LG cs.AI ·2026-10-19 ·Huangchao Xu, Baohua Zhang, Qian Liu, Zhong Jin, Yi Du
published similarity 0.63
Abstract · 20 pages, 7 figures

Drug--target affinity (DTA) prediction plays an important role in computer-aided drug discovery, where reliable computational models can help prioritize compound--protein pairs before experimental validation. A key challenge in DTA prediction is to effectively mine multi-level molecular information from drug structures while accurately modeling the binding-site environment of target proteins. To address these issues, we introduce HierDTA, a hierarchical structure-aware framework for DTA prediction. \textcolor{black}{HierDTA represents each drug as an atom--motif heterogeneous graph and introduces an augmentation module that propagates functional-motif semantics to the corresponding atoms. For proteins, kinase-domain structures are converted into residue interaction graphs. The resulting atom and residue representations are integrated using cross-attention to capture pair-specific relationships, while molecule fingerprints and pretrained ESM-2 embeddings provide complementary global information. Compared with state-of-the-art methods, HierDTA achieves superior performance on the Davis dataset across all metrics and attains the highest \(r_m^2\) of 0.791 on KIBA. It also exhibits strong generalization under cold-start settings, particularly on KIBA, where MSE is reduced by 21.7\% in the unseen-protein scenario. Ablation study and interpretability analysis supported the contributions of the hierarchical augmentation and interaction components.} Case studies further showed that HierDTA provided early enrichment of candidate bioactive compounds. These results indicate that HierDTA is an effective framework for affinity prediction and target-specific virtual screening.

0.31